

Foundational Competencies in Older Adult Mental Health

Psychopharmacology

References

Slide 6 - Normal Aging and Pharmacokinetics

1. Maher, D., Ailabouni, N., Mangoni, A. A., Wiese, M. D., & Reeve, E. (2021). Alterations in drug disposition in older adults: a focus on geriatric syndromes. *Expert opinion on drug metabolism & toxicology*, 17(1), 41–52. <https://doi.org/10.1080/17425255.2021.1839413>

Slide 7 - Normal Aging and Pharmacodynamics

2. Akhtar S. (2018). Pharmacological considerations in the elderly. *Current opinion in anaesthesiology*, 31(1), 11–18. <https://doi.org/10.1097/ACO.0000000000000544>
3. Thürmann P. A. (2020). Pharmacodynamics and pharmacokinetics in older adults. *Current opinion in anaesthesiology*, 33(1), 109–113. <https://doi.org/10.1097/ACO.0000000000000814>

Slide 8 - Complexity of Prescribing to Older Adults

4. Rochon, P. A. (2022, May 27). Drug prescribing for older adults. UpToDate. Retrieved June 21, 2022, from <https://www.uptodate.com/contents/drug-prescribing-for-older-adults/print#!>

Slide 13 - Address Stigma and Fears

5. Robb, C., Haley, W. E., Becker, M. A., Polivka, L. A., & Chwa, H. J. (2003). Attitudes towards mental health care in younger and older adults: similarities and differences. *Aging & mental health*, 7(2), 142–152. <https://doi.org/10.1080/1360786031000072321>
6. Robb, C., Chen, H., & Haley, W. E. (2002). Ageism in mental health and health care: A critical review. *Journal of Clinical Geropsychology*, 8(1), 1-12.
7. Knaak, S. Mantler, and Andrew Szeto. 2017. ". In *Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions*», *Healthcare Management Forum* (Vol. 30, No. 2, pp. 111-116).
8. Robb, C., Chen, H., & Haley, W. E. (2002). Ageism in mental health and health care: A critical review. *Journal of Clinical Geropsychology*, 8(1), 1-12.

Slide 17 - Cautious Prescribing in Older Adults

9. Beyer, J. L., & Johnson, K. G. (2018). Advances in pharmacotherapy of late-life depression. *Current psychiatry reports*, 20(5), 1-11.
10. Mulsant, B. H., Blumberger, D. M., Ismail, Z., Rabheru, K., & Rapoport, M. J. (2014). A systematic approach to pharmacotherapy for geriatric major depression. *Clinics in geriatric medicine*, 30(3), 517-534.

Slide 18 - Monitor Medications

11. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. *The lancet*, 356(9237), 1255-1259.

Slide 20 - Prescriber Resources

12. Beers, M. H., Ouslander, J. G., Rollinger, I., Reuben, D. B., Brooks, J., & Beck, J. C. (1991). Explicit criteria for determining inappropriate medication use in nursing home residents. *Archives of internal medicine*, 151(9), 1825-1832.
13. 2019 American Geriatrics society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2019;67(4):674

Foundational Competencies in Older Adult Mental Health

Psychopharmacology

References

Slide 23 - Selective Serotonin Reuptake Inhibitors (SSRIs)

14. Mulsant, B. H., Blumberger, D. M., Ismail, Z., Rabheru, K., & Rapoport, M. J. (2014). A systematic approach to pharmacotherapy for geriatric major depression. *Clinics in geriatric medicine*, 30(3), 517-534.

Slide 24 - Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

15. Jacobson, S. A., MD. (2014). *Clinical Manual of Geriatric Psychopharmacology, Second Edition*. American Psychiatric Association.
16. Beyer, J. L., & Johnson, K. G. (2018). Advances in pharmacotherapy of late-life depression. *Current psychiatry reports*, 20(5), 1-11.

Slide 25 - Atypical Antidepressants

17. Beyer, J. L., & Johnson, K. G. (2018). Advances in pharmacotherapy of late-life depression. *Current psychiatry reports*, 20(5), 1-11.

Slide 29 - Tricyclic Antidepressants

18. Jacobson, S. A., MD. (2014). *Clinical Manual of Geriatric Psychopharmacology, Second Edition*. American Psychiatric Association.

Slide 30 - Monoamine Oxidase Inhibitors

19. Jacobson, S. A., MD. (2014). *Clinical Manual of Geriatric Psychopharmacology, Second Edition*. American Psychiatric Association.

Slide 31 - Benzodiazepines

20. Maust, D. T., Blow, F. C., Wiechers, I. R., Kales, H. C., & Marcus, S. C. (2017). National trends in antidepressant, benzodiazepine, and other sedative-hypnotic treatment of older adults in psychiatric and primary care. *The Journal of clinical psychiatry*, 78(4), 21725.
21. Seppala, L. J., Wermelink, A., de Vries, M., Ploegmakers, K. J., van de Glind, E., Daams, J. G., van der Velde, N., & EUGMS task and Finish group on fall-risk-increasing drugs (2018). Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. *Journal of the American Medical Directors Association*, 19(4), 371.e11–371.e17.
<https://doi.org/10.1016/j.jamda.2017.12.098>
22. Paterniti, S., Dufouil, C., & Alperovitch, A. (2002). Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. *Journal of clinical psychopharmacology*, 22(3), 285–293. <https://doi.org/10.1097/00004714-200206000-00009>
23. Landi, F., Onder, G., Cesari, M., Barillaro, C., Russo, A., Bernabei, R., & Silver Network Home Care Study Group (2005). Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 60(5), 622–626.
<https://doi.org/10.1093/gerona/60.5.622>

Slide 33 - Antipsychotics or Neuroleptics

24. Maust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., & Kales, H. C. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. *JAMA psychiatry*, 72(5), 438–445.
<https://doi.org/10.1001/jamapsychiatry.2014.3018>

Foundational Competencies in Older Adult Mental Health

Psychopharmacology

References

25. Steinberg, M., & Lyketsos, C. G. (2012). Atypical antipsychotic use in patients with dementia: managing safety concerns. *The American journal of psychiatry*, 169(9), 900–906. <https://doi.org/10.1176/appi.ajp.2012.12030342>

Slide 36 - Anticholinergic Medications

26. Sura, S. D., Carnahan, R. M., Chen, H., & Aparasu, R. R. (2013). Prevalence and determinants of anticholinergic medication use in elderly dementia patients. *Drugs & aging*, 30(10), 837–844. <https://doi.org/10.1007/s40266-013-0104-x>
27. Rochon, P. A. (2022, May 27). *Drug prescribing for older adults*. UpToDate. Retrieved June 21, 2022, from <https://www.uptodate.com/contents/drug-prescribing-for-older-adults/print#>

Slide 41 - Postural Hypotension

28. Bhanu, C., Nimmons, D., Petersen, I., Orlu, M., Davis, D., Hussain, H., Magammanage, S., & Walters, K. (2021). Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials. *PLoS medicine*, 18(11), e1003821. <https://doi.org/10.1371/journal.pmed.1003821>

Slide 43 - Hyponatremia

29. Mangoni, A. A., & Jackson, S. H. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *British journal of clinical pharmacology*, 57(1), 6–14. <https://doi.org/10.1046/j.1365-2125.2003.02007.x>
30. Haack, S., Seeringer, A., Thürmann, P. A., Becker, T., & Kirchheiner, J. (2009). Sex-specific differences in side effects of psychotropic drugs: genes or gender?. *Pharmacogenomics*, 10(9), 1511–1526. <https://doi.org/10.2217/pgs.09.102>
31. Filippatos, T. D., Makri, A., Elisaf, M. S., & Liamis, G. (2017). Hyponatremia in the elderly: challenges and solutions. *Clinical interventions in aging*, 12, 1957–1965. <https://doi.org/10.2147/CIA.S138535>
32. Greenblatt, H. K., & Greenblatt, D. J. (2016). Antidepressant-Associated Hyponatremia in the Elderly. *Journal of clinical psychopharmacology*, 36(6), 545–549. <https://doi.org/10.1097/JCP.0000000000000608>
33. Nanba, K., Vaidya, A., & Rainey, W. E. (2018). Aging and Adrenal Aldosterone Production. *Hypertension (Dallas, Tex. : 1979)*, 71(2), 218–223. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10391>
34. De Picker, L., Van Den Eede, F., Dumont, G., Moorkens, G., & Sabbe, B. G. (2014). Antidepressants and the risk of hyponatremia: a class-by-class review of literature. *Psychosomatics*, 55(6), 536–547. <https://doi.org/10.1016/j.psych.2014.01.010>
35. Noohi, S., Do, A., Elie, D., Mahdanian, A. A., Yu, C., Segal, M., Looper, K. J., & Rej, S. (2016). Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients. *Current drug safety*, 11(2), 121–127. <https://doi.org/10.2174/1574886311666160226131603>

Slide 44 - Serotonin Syndrome

36. Tormoehlen, L. M., & Rusyniak, D. E. (2018). Neuroleptic malignant syndrome and serotonin syndrome. *Handbook of clinical neurology*, 157, 663–675. <https://doi.org/10.1016/B978-0-444-64074-1.00039-2>

Slide 45 - SSRI Discontinuation Syndrome

Foundational Competencies in Older Adult Mental Health

Psychopharmacology

References

37. Warner, C. H., Bobo, W., Warner, C., Reid, S., & Rachal, J. (2006). Antidepressant discontinuation syndrome. *American family physician, 74*(3), 449–456.

Slide 46 - Neuroleptic Malignant Syndrome (NMS)

38. Strawn, J. R., Keck, P. E., Jr, & Caroff, S. N. (2007). Neuroleptic malignant syndrome. *The American journal of psychiatry, 164*(6), 870–876.
<https://doi.org/10.1176/ajp.2007.164.6.870>
39. Keck, P. E., Jr, Pope, H. G., Jr, Cohen, B. M., McElroy, S. L., & Nierenberg, A. A. (1989). Risk factors for neuroleptic malignant syndrome. A case-control study. *Archives of general psychiatry, 46*(10), 914–918. <https://doi.org/10.1001/archpsyc.1989.01810100056011>